Akums Drugs reports Q2 FY27 results and acquires Oriflame India's manufacturing business
Akums Drugs · Pharmaceuticals & Biotechnology
What the filing says
- Q2 FY27 revenue ₹1,342 crore (up 31.9% YoY), EBITDA ₹195 crore (up 106% YoY), PAT ₹115 crore (up 168% YoY)
- Acquired Oriflame India's manufacturing business for ₹56 crore via subsidiary Pure & Cure Healthcare Pvt Ltd
- Acquisition includes two manufacturing facilities (Roorkee, Uttarakhand; Noida, Uttar Pradesh) and a leased warehouse in Noida
Why it's rated major development: the year-on-year change is 168% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other acquisition / merger filings this fortnight
- Krystal Integrated Services reports 46.25% Q2 FY27 revenue rise and acquires Citelum India
- Bondada Engineering Limited subsidiary Atpole acquires 51% stake in BTM Mobility
- Happiest Minds Q2 FY27 Revenues ₹645 Crores, Declares Interim Dividend ₹3.05/share
- Devyani International Q2 FY2027 results: revenue up 10.4% YoY, CCI approval for merger
- Castrol India Limited announces acquisition of Castrol Group Holdings by Acquirer
- Castrol India Limited discloses acquisition completion and equity restructuring
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.